 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] The SAMSUNG PHARM disclosed the change in the purpose of a civil suit filed by Biovill on the 5th and said it will respond to the indiscriminate filing of lawsuits in accordance with laws and procedures.
The lawsuit to change the purpose of the claim was filed by Biovill against Samsung Pharmaceutical Co. and seven others during the rehabilitation process in 2022, and the main goal is to change the amount of damages from 500 million won to 17.9 billion won.
Biovill has filed several lawsuits against past management during the previous rehabilitation, but all of them have been cleared of charges.
SAMSUNG PHARM has made it clear that it will respond in accordance with law and procedure to Biovill's actions that undermine corporate trust with repeated and irresponsible civil lawsuits.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
